The delivery of this research is of relevance for building confidence in imaging biomarkers: at present, with the exception of safety assessment of ARIA signals, the implementation of MRI in pharmaceutical clinical trials is still seen as exploratory rather than decision-making.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}